Cyclic adenosine monophosphate phosphodiesterase (cAMP PDE) (cAMP PDE)

Cyclic adenosine monophosphate (cAMP) phosphodiesterases are a group of enzymes that catalyze the hydrolysis of the second messenger cAMP into inactive 5'-AMP (StatPearls, 2023). By controlling the degradation of cAMP, these enzymes serve as essential regulators of intracellular signaling, influencing processes such as cell growth, differentiation, and immune response (PubMed, PMC7070373). The PDE superfamily includes several families that specifically target cAMP, most notably PDE4, PDE7, and PDE8, as well as dual-specificity families like PDE1, PDE2, and PDE3 (UniProt, 2024). In many inflammatory diseases, overactivity or specific localization of cAMP PDEs leads to reduced cAMP levels, promoting pro-inflammatory cytokine release and smooth muscle contraction (PubMed, PMC4017010). Consequently, pharmacological inhibition of these enzymes is a proven therapeutic strategy for conditions like chronic obstructive pulmonary disease (COPD), psoriasis, and heart failure (StatPearls, 2023). However, the broad distribution of PDE isoforms across various tissues can lead to off-target effects, such as gastrointestinal distress or cardiovascular issues, making the development of highly selective inhibitors a primary focus in modern drug design (PubMed, PMC5439513).

Other names

cAMP-specific phosphodiesterase3',5'-cyclic-AMP phosphodiesterasePDECyclic nucleotide phosphodiesterase

Inhibition of the phosphodiesterase enzyme prevents the hydrolysis of cAMP to 5'-AMP, thereby increasing intracellular cAMP concentrations and prolonging the activation of downstream effectors like Protein Kinase A (PKA) and Epac (StatPearls, 2023; PubMed, PMC7070373).